Biotech stocks with the highest free cash flow yield
Free cash flow over the last twelve months as a share of market value. As of .
- Ranked
- 17
- of 146 biotech stocks we cover
- Median
- 3.7%
- Highest
- 17.7%
- BCRX
- Range
- 1.1% to 17.7%
median 3.7%
1.1%17.7%
| # | Company | FCF yield | PE | Revenue growth (TTM) | Market cap |
|---|---|---|---|---|---|
| 1 | BCRXBiocryst Pharmaceuticals | 17.7% | n/m | +68.7% | $2.1B |
| 2 | INCYIncyte | 7.9% | 15.3× | +26.9% | $24.3B |
| 3 | EXELExelixis | 6.7% | 22.1× | +9.2% | $17.4B |
| 4 | NBIXNeurocrine Biosciences | 5.9% | 21.3× | +34.4% | $14.8B |
| 5 | HALOHalozyme Therapeutics | 5.5% | 38.5× | +41.2% | $14.6B |
| 6 | ADMAAdma Biologics | 4.7% | 15.8× | +8.0% | $2.5B |
| 7 | UTHRUnited Therapeutics | 4.2% | 21.6× | +2.5% | $25.9B |
| 8 | REGNRegeneron Pharmaceuticals | 3.8% | 24.0× | +9.3% | $100B |
| 9 | ALNYAlnylam Pharmaceuticals | 3.7% | 26.7× | +95.1% | $21.2B |
| 10 | PLXProtalix BioTherapeutics | 3.7% | 11.1× | +30.1% | $206.3M |
| 11 | ONCBeOne Medicines | 3.3% | 63.2× | +34.3% | $40.2B |
| 12 | VCELVericel | 3.0% | 88.1× | +23.0% | $2.1B |
| 13 | KRYSKrystal Biotech | 2.9% | 37.1× | +22.6% | $8.8B |
| 14 | TECHBIO-TECHNE | 2.3% | 63.2× | −0.4% | $11.4B |
| 15 | TARSTarsus Pharmaceuticals | 1.7% | n/m | +105.2% | $3.2B |
| 16 | MGTXMeiraGTx | 1.2% | 13.1× | n/m | $895.1M |
| 17 | RGENRepligen | 1.1% | 237× | +16.5% | $9.8B |
Not ranked: 76 with no positive free cash flow, 29 with not a meaningful number. 24 companies whose data behind this number has a caveat are left out until it is checked.
A ranking of numbers, not a recommendation. A low multiple can be a bargain or a business in trouble: open the company to see which.